Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

Hepatic adenoma is an uncommon, benign liver tumor. Benign means that it’s not cancerous. It’s also known as hepatocellular adenoma or liver cell adenoma. Hepatic adenoma is extremely rare. It most ...

Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...

You've had liver disease for a while, but now you notice something different about the way you act and feel. Maybe you forget things or get confused when someone's talking to you. Your friends may ...

Hepatic hydrothorax is a respiratory condition that affects people with cirrhosis and other serious liver issues. It occurs when fluid builds up in the pleural space. Hepatic hydrothorax is a ...

Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.

Organoid technologies have become a powerful emerging tool to model liver diseases, for drug screening, and for personalized treatments. Assoc. Prof. Tamer önder of Koç University and his team ...

Congenital hepatic fibrosis is a type of liver disease that is present from birth. It typically affects the function of the bile ducts and the veins that carry blood from the digestive tract to the ...

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...